Catherine Hildyard

Catherine Hildyard

Auto-generated profile, based on publicly available information

Catherine Hildyard

Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2017 in Blood Advances
Verified
Journal Article
Open access
PDF file
ABAlexander P. Bye
Alexander P. Bye
AUAmanda Jan Unsworth
Amanda Jan Unsworth
MDMichael J. Desborough
Michael J. Desborough
CHCatherine A. T. Hildyard
Catherine A. T. Hildyard
NANiamh Appleby
Niamh Appleby
JGJonathan M. Gibbins
Jonathan M. Gibbins
The Bruton tyrosine kinase (Btk) inhibitor ibrutinib induces platelet dysfunction and causes increased risk of bleeding. Off-target inhibition of Tec is believed to contribute to platelet dysfunction and other side effects of ibrutinib. The second-generation Btk inhibitor acalabrutinib was developed with improved specificity for Btk over Tec. We investigated platelet function in patients with non-Hodgkin lymphoma (NHL) receiving ibrutinib or acalabrutinib by aggregometry and by measuring thrombus formation on collagen under arterial shear. Both patient groups had similarly dysfunctional aggregation responses to collagen and collagen-related peptide, and comparison with mechanistic experiments in which platelets from healthy donors were treated with the Btk inhibitors suggested that both drugs inhibit platelet Btk and Tec at physiological concentrations. Only ibrutinib caused dysfunctional thrombus formation, whereas size and morphology of thrombi following acalabrutinib treatment were of normal size and morphology. We found that ibrutinib but not acalabrutinib inhibited Src family kinases, which have a critical role in platelet adhesion to collagen that is likely to underpin unstable thrombus formation observed in ibrutinib patients. We found that platelet function was enhanced by increasing levels of von Willebrand factor (VWF) and factor VIII (FVIII) ex vivo by addition of intermediate purity FVIII (Haemate P) to blood from patients, resulting in consistently larger thrombi. We conclude that acalabrutinib avoids major platelet dysfunction associated with ibrutinib therapy, and platelet function may be enhanced in patients with B-cell NHL by increasing plasma VWF and FVIII.

15 September 2015 in Anaesthesia
Verified
Journal Article
Open access
PDF file
CHC. Hildyard
C. Hildyard
NCNicola Curry
Nicola Curry

1 February 2016 in The Journal of Emergency Medicine
Verified
Journal Article
Closed access
CHCatherine Hildyard
Catherine Hildyard
PMPhilip Macklin
Philip Macklin
BPBernard Prendergast
Bernard Prendergast
YBYaver Bashir
Yaver Bashir

10 November 2014 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
CHCatherine Hildyard
Catherine Hildyard
DKDavid Keeling
David Keeling

10 January 2014 in BMJ Case Reports
Verified
Journal Article
Open access
PDF file
GCGeorge Chapman
George Chapman
CHCatherine Anne Thoroton Hildyard
Catherine Anne Thoroton Hildyard

21 November 2013 in BMJ Case Reports
Verified
Journal Article
Closed access
CHCatherine A T Hildyard
Catherine A T Hildyard
NGNeil J Gallacher
Neil J Gallacher
PMPhilip S Macklin
Philip S Macklin
We present a case of a 38-year-old woman who presented with symptoms suggestive of intra-abdominal or pelvic malignancy: marked weight loss, abdominal pain, altered bowel habit, anorexia and fatigue. The findings of multiple peritoneal deposits, adnexal and presacral masses on CT imaging and appearances on diagnostic laparotomy also suggested malignancy. However, the histological analysis was inconsistent with malignancy and revealed an infection with Actinomyces israelii. The patient started a course of intravenous antibiotics and complete resolution is expected. An intrauterine contraceptive device was identified as the likely source of the infection.